- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

CAREERS

BMS reveals new CEO

Bristol-Myers Squibb has announced that Lamberto Andreotti will take over as the company’s Chief Executive Officer when current Chairman and CEO James M. Cornelius retires.

Andreotti, who is currently President and Chief Operating Officer, has served with Bristol-Myers Squibb for 12 years in senior leadership roles, both internationally and in the US. Prior to joining Bristol-Myers Squibb, he held senior roles at KABI Pharmacia and then at Pharmacia & Upjohn.

Andreotti said: “Jim successfully led our transformation into a next-generation BioPharma leader with his strategic leadership and consistent focus on delivering our commitments.

“While challenges lie ahead, we are confident we can overcome them as we continue to successfully execute and deliver operationally, financially and strategically to maximise our future opportunities. As we succeed, the ultimate beneficiaries are patients who we help prevail against serious diseases.”

Cornelius was elected chairman of the Board of Directors in February of 2008 and was named interim CEO in September 2006, before taking on the role full-time in April 2007. During his time as CEO, Cornelius oversaw the company’s transformation to a leading next-generation biopharmaceutical company with a robust pipeline of innovative medicines for serious diseases. He will remain as chairman at the request of the Board.

Cornelius commented: “I have a high level of confidence in Lamberto and that is shared by everyone who has seen him consistently and successfully drive performance. Lamberto’s deep knowledge and insight of the BioPharma strategy make him the ideal leader as we transform into an industry benchmark.”

- Advertisement -

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription